Immunization with either an Escherichia coli recombinant segment of the human T-cell
lymphotropic virus (HTLV-III/LAV) envelope protein (gp120) or with deglycosylated gp120 …

In a study performed to determine which regions of the human T-cell lymphotrophic virus
type III (HTLV-III) may represent vaccine candidates to prevent the acquired immune …

Antibodies from the serum of patients with the acquired immune deficiency syndrome (AIDS)
or with the AIDS-related complex and from the serum of seropositive healthy homosexuals …

Human T-lymphotropic virus type III (HTLV-III) or lymphadenopathy-associated virus (LAV) is
tropic for human T cells with the helper-inducer phenotype, as defined by reactivity with …

Radiolabeled amino acid sequencing was used to characterize gp41, an antigen of HTLV-
III/LAV, the virus believed to be the etiological agent of the acquired immune deficiency …

In this study, two glycoproteins (gp160 and gp120) that are encoded by human T-cell
lymphoma virus type III (HTLV-III) were the antigens most consistently recognized by …

The discovery that the aetiological agent of acquired immune deficiency syndrome (AIDS) is
a retro virus, referred to as human T-lymphotropic virus type III (HTLV-III) or …

Two synthetic peptides containing amino acid sequences analogous to the envelope
glycoprotein of human T‐lymphotropic virus (HTLV) type III (HTLV‐III) and lymphadenopathy …

A newly identified protein from HTLV-III/LAV, the virus implicated as the etiologic agent of the
acquired immune deficiency syndrome, was studied. This protein, which has a molecular …

A monoclonal antibody was produced to the exterior envelope glycoprotein (gp120) of the
human T-cell lymphotropic virus (HTLV)-IIIB isolate of the human immunodeficiency virus …